Promosyon programı Indivior PLC
Gelişmiş program
Basit grafik
Şirket hakkında Indivior PLC
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. daha fazla ayrıntı| IPO date | 2014-12-29 |
|---|---|
| ISIN | GB00BN4HT335 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 12.24 |
| Дивиденд ао | 0.475 |
| Сайт | https://www.indivior.com |
| Цена ао | 9.69 |
| Günlük fiyat değişimi: | 0% (9.44) |
|---|---|
| Haftalık fiyat değişimi: | +3.62% (9.11) |
| Aylık fiyat değişimi: | -2.48% (9.68) |
| 3 ayda fiyat değişimi: | -15.79% (11.21) |
| Altı ayda fiyat değişimi: | +15.97% (8.14) |
| Yıllık fiyat değişimi: | -51.32% (19.39) |
| 3 yılda fiyat değişimi: | +995.13% (0.862) |
| 5 yılda fiyat değişimi: | +8 805.66% (0.106) |
| Yılbaşından bu yana fiyat değişimi: | -22.5% (12.18) |
|
|
Hafife alma
|
Yeterlik
|
|||||||||||||||||||||||||||||||||||||
Temettüler
|
Görev
|
Büyüme dürtüsü
|
|||||||||||||||||||||||||||||||||||||
| Kurumlar | Hacim | Paylaşmak, % |
|---|---|---|
| Two Seas Capital LP | 13670312 | 9.96 |
| Scopia Capital Management LP | 8311367 | 6.06 |
| Vanguard Group Inc | 5846354 | 4.26 |
| Goldman Sachs Group Inc | 5683038 | 4.14 |
| FMR, LLC | 5498087 | 4.01 |
| Artemis Investment Management LLP | 3127399 | 2.28 |
| Bank of America Corporation | 2701855 | 1.97 |
| Polar Capital Holdings PLC | 2621150 | 1.91 |
| Acadian Asset Management. LLC | 2281179 | 1.66 |
| Liontrust Investment Partners LLP | 1995889 | 1.45 |
| Süpervizör | İş unvanı | Ödeme | Doğum yılı |
|---|---|---|---|
| Mr. Mark Crossley | CEO & Executive Director | 2.34M | |
| Mr. Ryan Preblick | CFO & Executive Director | 1.14M | |
| Dr. Christian Heidbreder | Chief Scientific Officer | N/A | |
| Mr. Jason Thompson | Vice President of Investor Relations | N/A | |
| Ms. Cynthia Cetani | Chief Integrity & Compliance Officer | N/A | |
| Mr. Jeffrey W. Burris | Chief Legal Officer | N/A | 1972 (53 yıl) |
| Mr. Jon Fogle | Chief Human Resources Officer | N/A | |
| Mr. Richard Simkin | Chief Commercial Officer | N/A | |
| Mr. Hillel West | Chief Manufacturing & Supply Officer | N/A | |
| Mr. Vishal Kalia | SVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy Officer | N/A |
Adres: United States, North Chesterfield. VA, 10710 Midlothian Turnpike - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.indivior.com
Web sitesi: https://www.indivior.com
